<unk>  is indicated for the treatment of untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL). In the United States and the European Union it is also indicated for the treatment of relapsing forms of multiple sclerosis in adults. It is under investigation as a potential treatment for follicular lymphoma, diffuse large B cell lymphoma and rheumatoid arthritis.
Ofatumumab
Daratumumab
Alirocumab
Lanadelumab
Acalabrutinib
Tralokinumab
Sacituzumab govitecan
Bezlotoxumab